Defensins are small cationic proteins that harbor broadspectrum microbicidal activity against bacteria, fungi and viruses. This study examines the effects on pathogens of the epidermis engineered to express human beta-defensin 3 (HBD3) to combat bacterial infections. First, we examined the localization of HBD3 in the epidermis and observed HBD3 in the intercellular spaces and lamellar bodies of the upper epidermal layers. This result showed HBD3 expressed and assembled in the outer layers of the epidermis was suspected to counter the invading microorganisms. Next, we established a keratinocyte cell line that stably expressed HBD3 and found that the culture medium showed antibacterial activity. Furthermore, we prepared an epidermal sheet of these cells with the HBD3 gene and grafted this onto a dermal wound on a nude rat. The HBD3 engineered epidermis demonstrated significant antimicrobial activity. Skin ulcers without epidermis are constantly exposed to invading microorganisms. Biopsy samples of re-epithelizing epidermis from patients with skin ulcers were collected, and HBD3 mRNA level measured in the epidermis. The epidermal samples from the ulcer skin expressed 2.5 times higher levels of HBD3 transcript than those in the control skin. These results, taken together, indicate that the therapeutic introduction of the HBD3 gene into somatic cells may provide a new gene therapy strategy for intractable infectious diseases. Gene Therapy (2005) 12, 857-861.
The skin is always exposed to invading microorganisms, and is accordingly armed with several efficient defence systems. The synthesis of small, antimicrobial peptides was discovered within the last decade and these peptides are highly effective in directly killing microorganisms. The small (3-5 kDa) cationic defensins represent a critical peptide group among a growing number of microbicidal peptides that are capable of a broad spectrum of antimicrobial activity against many Gram-negative and Gram-positive bacteria, fungi, and certain viruses. 1, 2 Mammal defensins comprise genetically distinct a-and b-subfamilies of cationic tri-disulfide bridges. In humans, four types of human b-defensins (HBD), HBD1 through to 4 have been characterized thus far. [3] [4] [5] [6] HBD1, 2 and 3 have been identified in human skin and keratinocytes. HBD1 was initially isolated from hemofiltrates 3 and found to be constitutively expressed in various epithelia. 7 However, HBD1 does not appear as abundantly in the epidermis and is not upregulated in response to inflammation as are the other defensins. 5 HBD2 was isolated from the skin of patients with psoriasis and its expression was found in epithelial cells of the skin and the lung. HBD2 is inducible upon treatment with proinflammatory cytokines including TNF-a and interleukin 1, and when in contact with Pseudomonas aeruginosa bacteria. 8 HBD3 has also been isolated from psoriatic skin. 5 HBD1 and HBD2 shows antimicrobial activity predominantly against Gramnegative bacteria and these peptides are inactivated in physiologic salt concentrations, while HBD3 has a saltinsensitive broad spectrum activity that kills both Gramnegative and -positive bacteria including P. aeruginosa, Streptococcus pyogenes, multiresistant Staphylococcus aureus, and vancomycin-resistant Enterococcus faecium.
The use of conventional antibiotics provides the most powerful means to treat bacterial infections. However, the development of bacterial resistance against conventional antibiotics has emerged as a major public health concern. The appearance of resistant bacteria has been directly linked to the misuse and overuse of antibiotics in humans as well as in farm animals. This situation calls for the development of alternative strategies and therapies to fight infection. Defensins may turn out to be antibacterial agents with low susceptibility to resistance mechanisms, and thus gene therapy using these or the related genes is of great potential for treating intractable infectious diseases. [9] [10] [11] As mentioned above, HBD3 is salt-insensitive and is effective for Gram-positive bacteria, which are common cause of the skin infection. In this study, we introduced the HBD3 gene into a keratinocyte cell line and prepared the epidermal graft overexpressing HBD3 to determine the usefulness or feasibility of HBD3 engineered epidermis as a novel antibacterial therapy.
We first examined the localization of HBD3 in normal human control skin. Immunohistochemical analysis demonstrated that HBD3 was located predominantly in the upper spinous and granular layers of the epidermis (Figure 1a) . Immunoelectron microscopy showed gold particles in the intercellular spaces of the stratum corneum (Figure 1b) . Additionally, gold staining was observed in intracellular membrane-bound vacuoles, close to the apical surface of the granular layer plasma membrane presumed to be lamellar bodies (Figure 1c) . Also we used cathepsin D antibodies as control, because cathepsin D is a well-known component localized within lamellar bodes. 12, 13 Immunoelectron microscopy of similar sections (Figure 1d ) stained with both these antibodies showed that cathepsin D was also expressed within the lamellar body-like membrane-bound vacuoles just beneath the apical granular layer plasma membrane similar to HBD3.
Recently, HBD2 has also been shown to localize to the lamellar bodies and keratinocyte intercellular spaces.
14 Lamellar bodies used to be thought of as discrete granules that transport the contents from the Golgi apparatus to intercellular space. Recent evidence, however, has suggested a membrane folding model, in which the trans-Golgi network, lamellar bodes and intercellular space are all part of the same continuous membrane structure. 13, 15 In this system, the synthesized molecules are easily released into the extracellular space through a cell surface pore via a continuous membrane-bound tube. Since the lamellar body was first found exclusively associated with the outer surface of the stratum granulosum, a lamellar body-related secretory system must be present to enable high concentration of HBD2 and HBD3 molecules to reach the outer layer of the epidermis and form a defensive barrier containing enough HBD2 and 3 to be effective.
To establish a keratinocyte cell line that stably expresses HBD3, we first introduced the plasmid pFRT/lacZeo (Invitrogen, Carlsbad, CA, USA) into a human keratinocyte cell line, HaCaT cells, and subsequently prepared the Flp-In-HaCaT cells with the integrated Flp recombination target (FRT) site, which were also stably expressing b-galactosidase from the plasmid. Then, HBD3 cDNA was integrated into the FRT site already in the Flp-In-HaCaT cell genome, resulting in the establishment of an HBD3-HaCaT cell line. Immunostaining using anti-HBD3 antibodies showed that the cultured HBD3-HaCaT cell line expressed significant amounts of HBD3 (data not shown).
Our ultrastructural study showed that HBD3 was normally secreted though a special secretory system closely related to or identical with lamellar bodies in vivo ( Figure 1 ). We then wondered whether this transgene synthesis and transfer from keratinocytes was released HBD3 into the culture medium. Before examining the culture medium, the activity of synthetic HBD3 was estimated using Gram-positive S. aureus strains ATCC6538 (AT), SA015 (SA-1) and SA092 (SA-2). Synthetic HBD3 showed almost the same antimicrobial activity against the three S. aureus strains (Figure 2a ). It started to show killing activity in the microgram order and the concentration necessary to kill 50 % bacteria of SA-1 was approximately 8 mg/ml. Subsequently, colonyforming assays were performed to determine the antibacterial activity of HBD3-HaCaT cell culture medium. The apparent antimicrobial activity found from the 25 Â concentrated sample and 50% killing activity was observed in the 100 Â concentrated sample in SA-1 ( Figure 2b ). The supernatant of Fip-in-HaCaT cells as a control exhibited no killing activity against the bacteria.
To determine the precise concentration of HBD3 in the culture medium, we performed immunodot blot analysis. The concentration of HBD3 in HBD3-HaCaT cell culture medium was 9.2 ng/ml (Figure 3c ), while those of HaCaT and the Flp-In-HaCaT cells showed little or no detectable amount. Comparison with the result of synthetic HBD3 (Figure 2a) suggested that recombinant HBD3 from HaCaT cells had more antimicrobial activity than synthetic HBD3.
An epidermal sheet of HBD3-HaCaT cells was prepared and grafted onto an artificially induced ulcer in a nude rat (Figure 3a (1-3) ). Immunohistochemical analysis using an anti-HBD3 antibody found strong reactivity in the graft, HBD3 engineered epidermis, while little or no reactivity was seen in the control epidermis of grafted Flp-In-HaCaT cells (Figure 3a (4,5) ). The expression of HBD3 was stronger in the upper layers than the lower layers of the epidermis. On the other hand, Figure 1 (a) The localization of HBD3 was examined. Skin cryosections were cut from the biopsy skin specimens taken from normal volunteers and were incubated with the anti-human HBD3 rabbit polyclonal antibody (Novus Biologicals, Littleton, CO, USA). The second antibodies were goat anti-rabbit immunoglobulins conjugated to fluorescein (FITC). Immunostaining was detected as green (FITC) and the nuclear stain was observed as red (propidium iodide). HBD3 was located predominantly in the spinous and granular layers of the epidermis. (b-d) Immunoelectron microscopic analysis was performed. Normal skin samples were cryofixed with liquid propane cooled nitrogen, cryosubstituted at À801C and low temperature embedded at À601C in Lowicryl K11 M resin undergoing UV polymerization. Ultrathin sections were cut and immunogold stained using a 5 nm gold conjugated secondary (British Biocell, Cardiff, UK). 17 The antihuman HBD3 antibody and the anti-human cathepsin D rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used as primary antibodies and then a goat anti-rabbit IgG gold-conjugated secondary antibody (British Biocell, Cardiff, UK) was used. Gold particles were observed in the intercellular spaces of the stratum corneum (-) and in lamellar bodies of intracellular spaces (.) often seen immediately beneath the apical plasma membrane of granular layer keratinocytes. Magnification: HDB3; (b) 25 000 Â , (c) 60 000 Â ; cathepsin D; (d) 60 0000 Â .
Beta-defensin-3 engineered epidermis D Sawamura et al Figure 2 (a) Peptide HBD3 was chemically synthesized according to the cDNA sequence. 5 Bacterial strains, Gram-positive S. aureus: ATCC6538 (AT), SA015 (SA-1) and SA092 (SA-2), used for experiments. SA-1 and SA-2 were isolated from patients with skin infection that was sensitive to antibiotics and kindly given by Fujisawa Pharmaceutical Co., Ltd, Osaka, Japan. The bacteria were incubated with synthetic HBD3 in 200 ml of 10 mM sodium phosphate buffer (pH 7.4) containing 1% trypticase soy broth for 3 h at 371C. We measured the antimicrobial activity of HBD3 using the same media as used in the previous paper. 5 The antibiotic activity was estimated by plating serial dilutions of the incubation mixture and calculation of the colony-forming unit (CFU) after 24 h. (b) The human keratinocyte cell line HaCaT 18 was maintained in Dulbecco's modified Eagles's medium with 10% fetal bovine serum. FlpIn system (Invitrogen, Carlsbad, CA, USA) was utilized for generating stable expression cell line. In this system, Flp recombinase-mediated recombination occurs between specific Flp Recombination Target (FRT) sites. To integrate the FRT site into the genome of HaCaT cells, we first introduced plasmid pFRT/ lacZeo and selected for Flp-In-HaCaT cells by medium containing zeocin. Fip-in-HaCaT cells expressed a lacZ-Zeocin fusion gene could be also detected by b-galactosidase staining. To amplify the coding regions of HBD3 cDNA by PCR, we synthesized two primer sets, 5
0 -TTTAAGCTTAGCAGCTATGAG GATCC-3 0 and 5 0 -GGGCTCGAGGGTTTTTATTTCTTTC-3 0 for the HBD3 cDNA. PCR was performed with oligo-(dT)-primed human keratinocyte cDNA as template. The PCR fragments were digested with restriction enzymes and subcloned into a multicloning site of plasmid pcDNA5/FRT, in which the inserted cDNA was driven by the CMV promoter. We performed co-transfection of the pcDNA5/FRT with HBD3 cDNA and the Flp recombinase expression vector pOG44. c) The concentration of HBD3 in the culture medium was determined by immunodot blot analysis. 16 Positive control and standard curve were generated with synthetic HBD3 peptides. Briefly, 5 ml of the concentrated medium (from the above samples) and serially diluted synthetic HBD3 were dotted in triplicate on nitrocellulose membrane. The membrane was incubated with the anti-human HBD3 rabbit polyclonal antibodies at 41C overnight, and then reacted with goat anti-rabbit antibodies conjugated with peroxidase at room temperature for 2 h. The resultant dot complexes were processed for Phototope HRP Western Blot Detection System (Cell Signaling, Beverly, MA, USA) according to the manufacturer's protocol. The amount shown represents the mean7s.d. of three individual samples. Figure 3 (a) In nude rats (F344/N Jcl-rnu), the sites for transplantation were prepared by excising a 2 cm 2 area of dorsal epidermis and dermis. The confluent cultures of HBD3-HaCaT and control Flp-In-HaCaT were treated with dispase (1 nU/ml:Godo Shusei, Japan), and the floating epidermal sheet was placed on the prepared site of the nude rat. An occlusive dressing was quickly placed over the graft to hold it in position and to prevent it from drying. After 7 days, the skin sample was taken by excision. Afterwards, routine hematoxylin-eosin staining (1-3), immunostaining of the HBD3 antibody (4,5) and b-galactosidase staining (6,7) were performed. (1) normal rat; (2,4,6) the skin from Flp-In-HaCaT; (3,5,7) the skin from HBD3-HaCaT. (b) At 5 days after transplantation, the serial dilution of bacterial culture of SA-1 was applied to the graft and was overlaid with an occlusive dressing in wet condition. After 8 h incubation, the samples were collected from the surface of the graft with a sterile cotton swab, and transferred to the culture medium. The CFU was measured by plating. In each experiment, the CFU from the sample of HBD3-HaCaT was expressed as the rate against that of control Flp-InHaCaT. Each group consisted of five rats and each value shown represents the mean7s.d. of five individual samples. The student t-test detected a significant difference, Po0.01; Cont versus HBD3. (c) We excised the rat epidermis surrounding both the control and HBD3 grafts. Epidermal sheets were obtained from the skin samples by treatment with 10 mg/ml dispase (3 h at 371C). 19 Keratinocyte suspensions were obtained from these epidermal sheets by a further 0.25% trypsin treatment (30 min at 371C). Total RNA was extracted from cultured cells and first strand cDNA was synthesized with reverse transcriptase (Life Sciences Inc., St Petersburg, FL, USA) using an oligo-dT primer. PCR was performed using following primers: Beta-defensin-3 engineered epidermis D Sawamura et al b-galactosidase staining showed strong activity in the control epidermis, but not in the HBD3 engineered epidermis (Figure 3a (6,7) ). To ascertain the precise antimicrobial activity of the engineered skin, we applied bacteria SA-1 to the grafted epidermis and performed a colony-forming assay. The results demonstrated that significant antibacterial activity (Po0.01) was present in the HBD3 engineered epidermis compared with the control epidermis (Figure 3b) . We examined the effect of the rat's endogenously produced antimicrobial peptides from the surrounding skin of the HBD3 and control grafts, but could not detect difference in expression of rat cathelicidine cathelin-related antimicrobial peptide (CRAMP) or BD3 (Figure 3c) .
We demonstrated HBD3 killing activity in the culture medium; however, the HBD3 concentration in the supernatant was only 9.2 ng/ml, which was insufficient for significant antimicrobial activity. Therefore, we postulated that this HBD3 engineered epidermis might not show any significant antibacterial activity in vivo. However, our results showed that the HBD3 gene transfected epidermis formed an effective barrier that could withstand the attack of invading bacteria. These data suggested that the conditions in vivo might be a more suitable environment for keratinocytes to produce HBD3 and also utilize a more 'normal' lamellar bodyrelated secretory system already in place for HBD3 in the appropriate position to prevent or protect from microorganism attack.
One of the worst situations for preventing the tissue from bacterial invasion is in skin ulcers without any epidermal covering. If HBD3 plays a critical role in defending bacterial invasion in the skin, we hypothesized that re-epithelizing epidermis surrounding the ulcer wound might express a much higher level of HBD3. We therefore collected skin samples from patients with skin ulcers and examined the expression of HBD3 mRNA levels in the epidermis. As we expected, the epidermal samples in the ulcer skin expressed 2.5 times higher levels of HBD3 transcript than those in control skin (Figure 4 ). This result also suggested an increase in defensin expression as one of the major antimicrobial defense systems that can form an effective response to protect tissue from bacterial invasion.
Atopic dermatitis is a chronic inflammatory intractable skin disorder with unknown etiology. Atopic dermatitis skin lesions are often associated with higher than normal bacterial and viral infections, and atopic dermatitis skin has demonstrated a significant decrease expression of cathelicidin LL-37 and HBD2. 16 This evidence also led us to introduce the HBD3 gene into the epidermis and we have proved that the HBD3 gene transfected epidermis had a highly protective shield against bacterial invasion. The gene therapeutic introduction of HBD3 gene or the related genes into somatic cells may provide a new strategy for gene therapy for intractable infectious diseases. Figure 4 The skin samples were collected from six patients with skin ulcer resulting from trauma and deep dermal burn during treatment at the Hokkaido University Hospital. Informed consent was obtained from individual subjects. We selected the patients with re-epithelizing ulcers at the healing stage, but the ulcer was so large that complete epithelization was expected to take a considerable time and to lead to hypertrophic scar formation. During operations we removed the skin samples from the ulcer with 0.5 cm margin. To prepare keratinocytes, we first separated the epidermis from dermis and subcutaneous tissue. Normal skin samples were obtained from seven patients undergoing reconstructive plastic surgery. Epidermal sheets were obtained from the skin samples by treatment with 10 mg/ml dispase (3 h at 371C). 19 Keratinocyte suspensions were obtained from these epidermal sheets by a further 0.25% trypsin treatment (30 min at 371C). Total RNA was extracted from cultured cells and first strand cDNA was synthesized with reverse transcriptase (Life Sciences Inc., St Petersburg, FL, USA) using an oligo-dT primer. Assays-on-Demandt Products for HBD3 and GAPDH were purchased from Applied Biosystems (Foster City, CA, USA). The 50 ml reaction in each well contained 1 ml of total cDNA, 300 nm of sequence-specific primers and 200 nm of dual-labeled fluorogenic probe in 1 Taqman Universal PCR master mix (Applied Biosystems). A negative PCR control without template and a positive PCR control with a template of known amplification were included in each assay. The reaction was performed in an ABI PRISM 7700 Sequence Detection System. The HBD3 specific signal was normalized by constitutively expressed GAPDH and expressed as arbitrary scale. Ulcer: ulcer skin samples, Cont: normal skin samples. Each value indicated the mean7s.d. The student's t-test detected a significant difference, Po0.01; Cont versus Ulcer.
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